We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Optimizing Treatment With Ibrutinib in High-Risk CLL

Saturday, February 7, 2015

Richard Furman, M.D., director of Weill's CLL Research Center, participates in a panel discussion via OncLive about therapy for patients with chronic lymphocytic leukemia (CLL) whose tumors harbor a 17p deletion (a group that only represents about 5 percent to 10 percent of patients at the time of initial treatment) with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib.